Sample analysis device, testing apparatus, and sensor cartridge
US-9222889-B2 · Dec 29, 2015 · US
Label-free detection of sialic acid using surface-enhanced Raman scattering microscopy
US10845312B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10845312-B2 |
| Application number | US-201615746360-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 22, 2016 |
| Priority date | Jul 22, 2015 |
| Publication date | Nov 24, 2020 |
| Grant date | Nov 24, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Certain embodiments are directed to systems and methods using surface enhanced Raman scattering (SERS) detection. More specifically, the present invention describes a system and method of use for SERS detection of sialic (N-acetylneuraminic acid) using citrate-reduced silver nanoparticles.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for identifying a subject with cancer by detecting a N-acetylneuraminic acid analyte in a saliva sample from the subject comprising: (a) contacting the sample from a subject suspected of having cancer with a citrate reduced silver nanoparticles forming a N-acetylneuraminic acid silver nanoparticle complex; and (b) measuring N-acetylneuraminic acid analyte levels in the sample using label-free detection of the analyte by surface enhanced Raman scattering (SERS) of the N-acetylneuraminic acid/silver nanoparticle complex, wherein an increased level of N-acetylneuraminic acid analyte relative to a control is indicative of the subject having cancer. 2. The method of claim 1 , where the cancer is breast cancer. 3. The method of claim 1 , wherein a cancer positive sample has a N-acetylneuraminic acid analyte concentration greater than 7 mg/dL. 4. The method of claim 1 , wherein the sample volume is less than 20 μL. 5. The method of claim 1 , wherein the sample is pretreated before performing steps (a) and (b).
Assignees
Inventors
Classifications
of the breast · CPC title
Nanosized particles · CPC title
by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy (A61B5/0071 takes precedence) · CPC title
Breast evaluation or disorder diagnosis (optical mammography A61B5/0091) · CPC title
Bones (A61B5/4547 takes precedence) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10845312B2 cover?
- Certain embodiments are directed to systems and methods using surface enhanced Raman scattering (SERS) detection. More specifically, the present invention describes a system and method of use for SERS detection of sialic (N-acetylneuraminic acid) using citrate-reduced silver nanoparticles.
- Who is the assignee on this patent?
- Vinogradova Ekaterina, Navarro Contreras Hugo, Jose Yacaman Miguel, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification G01N21/658. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).